Immunotherapy, in which cells from the human immune system are unleashed to fight disease, has been the big story in cancer treatment over the past few years. When it works, it can spur long-lasting remission in patients for whom other treatments have failed. But most patients don’t benefit, and there is still no good way to predict who will respond.
The Society for Immunotherapy of Cancer, SITC, selected Gabrielle Romain, post-doctoral research fellow in the UH Cullen College of Engineering, to present her research on cancer immunotherapy at its 30th anniversary annual meeting. With an approximate $750 travel grant, she plans to attend the conference in National Harbor, Maryland, in November.
Immunotherapy, a cancer treatment that utilizes the body’s own immune system to attack cancer cells, has garnered great interest as a relatively new field of medicine that offers an alternative to traditional chemotherapy.
Researchers have created a new method for screening cells used in immunotherapy cancer treatments, allowing high-performing immune system cells to be studied in isolation and potentially expanding the number of patients for whom the breakthrough treatment proves successful.
Researchers are gaining momentum with adoptive cell therapy (ACT), a type of immunotherapy that uses the patients’ native or genetically modified immune cells to attack diseases such as cancer and chronic infection.
Almost 19,000 new cases of acute myeloid leukemia and 10,500 deaths from the blood and bone marrow cancer could strike Americans this year, according to the American Cancer Society. Chemotherapy, when used as primary treatment, is successful in about 65 percent of patients with the cancer, and remission rates vary depending on patients’ individual characteristics, according to the organization.
At this month’s Cullen College of Engineering faculty and staff meeting, Dean Joseph Tedesco announced the recipients of the 2013–2014 teaching awards, which recognize faculty members with outstanding performance in teaching, research and service.
A professor with the University of Houston Cullen College of Engineering has won a grant from the Melanoma Research Alliance to help develop one of the most promising therapies for patients with the disease.
A professor with the University of Houston Cullen College of Engineering has won his second major cancer research grant in four months, giving him a total of nearly $3.4 million to help develop cutting-edge treatments for the disease.
Graduate students and faculty members with the University of Houston Cullen College of Engineering have found a way to turn bacteria’s infection process into something that can actually benefit humans.
Cullen College of Engineering undergraduates showcased their semester-long research in poster presentations at the inaugural UH Spring Undergraduate Research Symposium on April 12, held at the university’s Rockwell Pavilion. Students represented mentored work in biomedical, chemical, civil, electrical, and mechanical engineering programs.
A researcher with the UH Cullen College of Engineering has published an article in one of the nation’s foremost scientific journals outlining successful efforts to rapidly identify and characterize immune system cells that fight HIV.
Students from the University of Houston Cullen College of Engineering spent their summer conducting research as part of the 2011 Summer Undergraduate Research Fellowship (SURF) program. The fellowship provides funding for sophomores, juniors and seniors in any major to experience hands-on research on a full-time basis for 10 weeks.
A UH Cullen College of Engineering professor has received a grant to develop a new method of testing potential vaccines, and will use this approach to fight a virus identified as an emerging bioterrorism threat.